New Big Money Means Acelyrin Inc (SLRN) Investors Could Reap Benefit

Acelyrin Inc (NASDAQ: SLRN) is 9.79% higher on its value in year-to-date trading and has touched a low of $5.70 and a high of $29.88 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SLRN stock was last observed hovering at around $7.79 in the last trading session, with the day’s gains setting it 0.4%.

Currently trading at $8.19, the stock is 14.27% and 13.91% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.01 million and changing 5.13% at the moment leaves the stock -45.35% off its SMA200. SLRN registered a loss of -67.88% in past 6-months. The firm has a 200-day simple moving average (SMA200) of -$0.02.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


Sponsored

The stock witnessed a 6.64% gain in the last 1 month and extending the period to 3 months gives it a -10.98%, and is 0.61% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.77% over the week and 7.49% over the month.

Distance from 52-week low is 43.68% and -72.59% from its 52-week high.

Acelyrin Inc quarterly earnings per share for the current quarter are estimated at -$0.99.The EPS is expected to grow by 66.16% this year

154 institutions hold shares in Acelyrin Inc (SLRN), with institutional investors hold 111.08% of the company’s shares. The shares outstanding are 92.70M, and float is at 61.29M with Short Float at 10.01%. Institutions hold 88.18% of the Float.

The top institutional shareholder in the company is Ayurmaya Capital Management Company, LP with over 9.33 million shares valued at $195.1 million. The investor’s holdings represent 9.60% of the SLRN Shares outstanding. As of Jun 29, 2023, the second largest holder is FMR, LLC with 7.46 million shares valued at $155.84 million to account for 7.67% of the shares outstanding. The other top investors are Citadel Advisors Llc which holds 6.04 million shares representing 6.21% and valued at over $126.23 million, while Orbimed Advisors LLC. holds 5.48% of the shares totaling 5.33 million with a market value of $111.32 million.

Acelyrin Inc (SLRN) Insider Activity

A total of 10 insider transactions have happened at Acelyrin Inc (SLRN) in the last six months, with sales accounting for 1 and purchases happening 9 times. The most recent transaction is an insider sale by Lin Shao-Lee, the company’s Chief Executive Officer. SEC filings show that Lin Shao-Lee sold 10,691 shares of the company’s common stock on Jan 02 at a price of $7.41 per share for a total of $79188.0. Following the sale, the insider now owns 1.6 million shares.

Acelyrin Inc disclosed in a document filed with the SEC on May 09 that Westlake BioPartners Fund II, (10% Owner) bought a total of 1,250,000 shares of the company’s common stock. The trade occurred on May 09 and was made at $18.00 per share for $22.5 million. Following the transaction, the insider now directly holds 9.79 million shares of the SLRN stock.

Still, SEC filings show that on May 09, SEIDENBERG BETH C (Director) acquired 1,250,000 shares at an average price of $18.00 for $22.5 million. The insider now directly holds 9,790,729 shares of Acelyrin Inc (SLRN).